what is being set up is sarepta could be caught up to its big competitor in the space, biomarin which has a truck that can compete with a sarepta drug and because they can file for approval they might go into a back-to-back fda advisory committee meeting this year, potentially in the fall, when an outside panel of experts meets to discuss whether the drug should get approved. analysts are saying deutsche bank thinks the stock could go up to 46 with a positive panel and down below 12 and parade is even stronger and the outcome of this panel could drive the stock above 100 or below 10 so this is a real big event. >> sounds like we need our options guy. >> the room may not be big enough. sarepta versus biomarin now potentially at the end of the year. >> how does the fact that they are back-to-back hearings impact the outcomes, if at all? >> well, a lot of people thought sarepta would not catch up to biomarin, almost like a david and goliath, 20 billion market cap company that has brought a rare disease drugs through the fda and why a lot of people thought they would be way in the lead. s

we are talking about biomarin. this might be floating on people's radar screens. analysts upgraded the stock to 1401, 50 both from 125 price targets. so ahead of a couple catalysts this year. the nearest term one is a drug called bmm 111. it's for a condition called a con droe place yeah. it's the most common form of dwarfism. achondroplasia affects 14,000 people in the u.s. there is a higher rate of infant mortality among kids with achon achondroplasia. bmm 111 is expected to read out in june. analysts say the drug could drop more than $1 billion in peak annual revenue if it's successful. investors haven't necessarily priced this in. they may not be sure what to expect from these data. and jpmorgan was looking at some of the options saying that they're only pricing in maybe a 6% move to the up side or down side. if these data are very positive, you could see a bigger potential move. >> a billion dollar drug before the cost of a treatment of $400,000, correct? >> it could be up there with all of these rare drug treatments. only a few thousand patients in the unite

companies like biomarin all of these companies going way up in trading today.arket. these are rare assets valuable assets because of how much they can bring in and charge for the drugs. we could see more here but this is obviously contributing to the bubble. >> what a day, what a year. thank you so much. when we come back lending club beating expectations for the first quarter. stocks up 6% today, nearly 20% since december. we're going to be joined with the results and tell us why the accompany has been raising revenue outlook for the year. dow is down and squawk on the street continues in a moment. [ male announcer ] whether it takes 200,000 parts ♪ ♪ 800,000 hours of supercomputing time 3 million lines of code, 40,000 sets of eyes, or a million sleepless nights. whether it's building the world's most advanced satellite, the space station, or the next leap in unmanned systems. at boeing, one thing never changes. our passion to make it real. ♪ ♪ >>> shares of lending club are jumping up this morning after the accompany reported better than expected earnings. jo

. >> if we're going to do a speculative we like receptor and radius and biomarin.how about ben in florida? >> caller: booyah from miami florida. >> nice. >> got to ask you, is it time to call pbr some love? >> no i've been drinking the yuengling lately -- oh the bad oil company from brazil. let's take a pass on that. charlotte from new york. >> caller: jim? i would like your opinion on go go please. >> a lot of people got too negative on gogo. the stock has been red shot. i'm still on the fence because i want this to be able to load better but the buyers are speaking loudly. the shorts are covering. how about we go to dave in new jersey. dave? >> how are you doing jim? a big booyah. >> thank you. >> my question is kite pharmaceuticals. >> i like it. but you have to go down blue bird they have real stuff happening now. ron in arizona, ron. >> caller: yes. >> go ahead, ron. >> caller: professor, cramer long time listener. >> thank you. >> caller: i was wondering about your view on medtronics. >> i like it. i'll see you medtroincs and raise you life science. it's st.

which is why we said we like biomarin, resentos and radios. those three. go to john in california. >> caller: thank you for taking my call. my question is what do you think about juno. >> like halo. speculative stuff. to take a long term view someone is going to win in the personalized medicine category. let's go to scott in virginia. >> caller: booyah jim, talk to me about kmx. >> car max is extraordinarily strong. and let me tell you when you think of retailers it wouldn't be so bad to own car max or auto nation. that, ladies and gentlemen, is the conclusion of the lightning round. >> the lightning round is sponsored by td ameritrade. >>> as i sat mesmerized in my jammies watching the s&p futures get pounded -- no they are not feet pajamas as german bonds roeld rolled over in the wee hours of the morning. let's get scary sounds like stephen king. i'll be watching in my jammies again tonight. there is a sight. >> caller: hi, jim, you are my apple watch. you take my financial pulse at 9:00 a.m. and 6:00 p.m. every week day. thank you. >> you are quite welc

and that better company is biomarin pharma. i would rather see you in bmrn than i would see you in srpt. >>> all right. together is better. i expect more m and a mania next week and good numbers from companies reporting, a bunch of them. keep track of some of these. i got to tell you. avago, costco, pallo alto. money will be made here. >>> i'll talk about a good stock despite red ink. >>> i'll talk to companies benefitting from the outbreak of -- >>> plus how one company is helping some of the most elite members of the united states military make the traps eggs from the battlefield to the board room. stick with cramer. >>> don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer. #madtweets. send jim an e-mail to madmoney at cnbc.com. or give us a call at 1-800-743-cnbc. miss something? head to madmoney.cnbc.com. there's some facts about seaworld we'd like you to know. we don't collect killer whales from the wild. and haven't for 35 years. with the hightest standard of animal care in the w

another one we're watching is biomarin, another one in the rare disease drug maker space.he other and makes drugs for the orphan disorders. that's an $18 billion market cap. this is both a takeout target but also a potential acquirer itself. that's another interesting one to watch. finally we're talking about aread pharmaceuticals. that makes a cancer drawing called iclusiv. it has an activist investor on the board who just made a settlement to have the ceo retire. a lot of speculation around that name. cancer drugs and drugs for orphan diseases rare diseases are the two most talked about hot spaces in biotech now. those are the three people are watching. a lot of the other ones on the horizon. the premiums are getting very high. >> absolutely. let the speculation begin. let's trade biotech. you're long ibb. you have to have a strong stomach. >> yes recently it's been nauseating for sure. xbi, ibb, fbt, we've owned all three for a long long time. you have to be prepared to stomach the volatility. the reason i own the etfs, i am not prepared to stomach the volatility of own

biomarin. that stock has been clobbered. that would be my pick to go back to where it was.lio. reminds me a lot of genzyne. biotech is not done. >> what is on mad tonight? >> there are a couple of stocks i think you'll be surprised i decided to go positive on that i've been negative. we've got a company with natural and organic food. and pool corp. and del frisco's. we'll learn about it. >> i'm hungry looking at that promo right there. >> it's a great place to go. >> great week and a good weekend to you. >> congratulations to the staff and everybody. did such a great job out in san francisco. >> a lot of people worked hard to make it happen. see you tonight "mad money." when we come back ism, construction spending and the ceo of expedia. don't go anywhere. hello. i am here to offer sophisticated investing strategies. my technology can help you choose the right portfolio. monitor it. and automatically rebalance it. all without charging advisory fees, account service fees or commissions. that may be hard to compute. but i'm a computer. so trust me. it computes. say hello at i

it is head-to-head with another company biomarin. up 30% in after hours. we got other biotech news.5. entering into a worldwide partnership with johnson & johnson to develop hepatitis c drugs. worth up to $1.1 billion. and j and j is taking an equity investment worse $225 million. big biotechnical news. back to you. >>> we'll keep an eye on it. doufs the dow was up. bank of america predicting scary summer. goldman sachs saying the markets are going nowhere. joining me now with his view on what investors should do is alexander freeman, former cio at ibs. welcome to the program. where your putting that $127 billion? >> well luckily a lot of great managers who are investing. you start with the observations people are nervous. why? in a sense they just have to sit in the boat for the last three years and going in the right direction. that's the monetary policy. that's moving in the other direction. they've paddle and asking a question which they haven't asked and that is which way do we paddle. it's almost shock to think about it that way. that's where you start with. the question is do

>> check out shares of biomarin.n does the company have a drug in the pipeline that could propel it even higher? the answer tonight at 5:00 on "fast." >> biotech still doing very well. we look forward to that at 5:00 p.m. eastern. folks, thank you for watching closing bell -- >> closing bell's next. >>> yes, thanks everybody for watching "closing bell." i'm kelly evans here at the new york stock exchange. >> i'm bill griffeth. welcome to the most important hour of the trading day. we say that all the time. it is not just because we think it because it is our show. there's a new study out. you're going to find this very interesting. you'll find out why many on wall street say the last 30 minutes of tradesing ingtrading are indeed so critical to the trading day. >>> goproup 7% as the company reveals its plan to get into virt oolual reality and drones. we have someone who says this

i would not go against biomarin. >> good guys. >> all right. we'll be watching. we have more. spencer capitalist and a programming note since leavinge j.c. penny coming up at 11:30 a.m. eastern time. squawk box will be right back. boys? stop less. go more. the passat tdi clean diesel with up to 814 hwy miles per tank. just one reason volkswagen is the #1 selling diesel car brand in america. >>> welcome back. now we're going to spend a last couple of minutes with our guest host for the morning. j.b., question for you. all the things you're investing now. you're not in grub hub, we know. what's the single best thing you got going? >> well we just announced a transit action yesterday actually for a accompany. it's a accompany revolutionizing in old line industries and property management. technology invading a whole bunch of old line industries. >> did you build that to help with your hotels and other building properties. >> no. it was an entrepreneur in chicago built it from scratch. he had been in the old line industry. understood the industry better than anybody.